PE20121689A1 - Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos - Google Patents
Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismosInfo
- Publication number
- PE20121689A1 PE20121689A1 PE2012000444A PE2012000444A PE20121689A1 PE 20121689 A1 PE20121689 A1 PE 20121689A1 PE 2012000444 A PE2012000444 A PE 2012000444A PE 2012000444 A PE2012000444 A PE 2012000444A PE 20121689 A1 PE20121689 A1 PE 20121689A1
- Authority
- PE
- Peru
- Prior art keywords
- glycosilation
- advanced
- receiver
- final products
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL QUIMERICO HUMANIZADO QUE SE UNE AL RECEPTOR PARA PRODUCTOS FINALES DE GLICOSILACION AVANZADA (RPFGA) QUE COMPRENDE A) UN DOMINIO VARIABLE DE CADENA LIGERA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº 1 A 23 O UNA VARIANTE FUNCIONALMENTE ACTIVA; B) UN DOMINIO VARIABLE DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº 24 A 46 O UNA VARIANTE FUNCIONALMENTE ACTIVA; Y C) UN DOMINIO CONSTANTE DE INMUNOGLOBULINA DE CADENA PESADA TAL COMO IgM, IgG1, IgG2, IgG3, IgG4, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, DIABETES, AMILOIDOSIS, ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09290778A EP2308896A1 (en) | 2009-10-09 | 2009-10-09 | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
EP09290845A EP2319871A1 (en) | 2009-11-05 | 2009-11-05 | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20121689A1 true PE20121689A1 (es) | 2012-12-14 |
Family
ID=43448431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000444A PE20121689A1 (es) | 2009-10-09 | 2010-10-08 | Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos |
Country Status (19)
Country | Link |
---|---|
US (1) | US20120282637A1 (es) |
EP (1) | EP2486058A1 (es) |
JP (1) | JP2013507115A (es) |
KR (1) | KR20120089863A (es) |
CN (1) | CN102686611A (es) |
AU (1) | AU2010305374A1 (es) |
BR (1) | BR112012007821A2 (es) |
CA (1) | CA2777237A1 (es) |
CL (1) | CL2012000886A1 (es) |
CR (1) | CR20120139A (es) |
EC (1) | ECSP12011787A (es) |
IL (1) | IL218968A0 (es) |
MA (1) | MA33661B1 (es) |
MX (1) | MX2012004090A (es) |
PE (1) | PE20121689A1 (es) |
RU (1) | RU2558301C2 (es) |
TN (1) | TN2012000138A1 (es) |
WO (1) | WO2011042548A1 (es) |
ZA (1) | ZA201202099B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
GB201200563D0 (en) * | 2012-01-13 | 2012-02-29 | Imp Innovations Ltd | Binding molecule |
WO2014167826A1 (ja) * | 2013-04-08 | 2014-10-16 | 株式会社免疫生物研究所 | アミロイド前駆体タンパク質のα-セクレターゼ切断後のC末端側断片の切断面を特異的に認識する抗体及びその利用 |
WO2014197460A1 (en) * | 2013-06-04 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies |
CN105814079B (zh) | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
EP3077823B1 (en) | 2013-12-05 | 2019-09-04 | The Broad Institute, Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
WO2016061532A1 (en) * | 2014-10-16 | 2016-04-21 | The Broad Institute Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
JP6679096B2 (ja) * | 2014-10-21 | 2020-04-15 | 学校法人 久留米大学 | Rageアプタマーおよびその用途 |
US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
JP6913030B2 (ja) | 2015-05-18 | 2021-08-04 | アジェンシス,インコーポレイテッド | Axlタンパク質に結合する抗体 |
WO2016201368A1 (en) | 2015-06-10 | 2016-12-15 | The Broad Institute Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
WO2016201319A1 (en) * | 2015-06-10 | 2016-12-15 | The Broad Institute Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
JP6578595B2 (ja) * | 2015-08-28 | 2019-09-25 | 国立研究開発法人科学技術振興機構 | 抗アセチル化ヒストンh4抗体 |
KR20180041136A (ko) * | 2015-09-08 | 2018-04-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-epha4 항체 |
CN108601828B (zh) | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
EP3389715A4 (en) | 2015-12-14 | 2019-06-12 | David K. Thomas | COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION |
CN113512111B (zh) * | 2017-03-10 | 2023-08-15 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
AU2018312222A1 (en) | 2017-08-02 | 2020-02-27 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
AU2019247511A1 (en) | 2018-04-06 | 2020-10-22 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
US11345744B2 (en) | 2019-05-07 | 2022-05-31 | William R Church | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same |
CN114222760A (zh) * | 2019-06-26 | 2022-03-22 | 葛兰素史密斯克莱知识产权发展有限公司 | Il1rap结合蛋白 |
JP2022551603A (ja) | 2019-10-03 | 2022-12-12 | エータイアー ファーマ, インコーポレイテッド | 抗nrp2抗体を含む組成物および方法 |
WO2022019924A1 (en) * | 2020-07-23 | 2022-01-27 | Church William R | Antibody specific to staphylococcus aureus, therapeutic method and detection method using same |
CN113956363B (zh) * | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd47和cd24的重组融合蛋白及其制备和用途 |
CN116554311B (zh) * | 2023-05-04 | 2023-11-21 | 中国人民解放军军事科学院军事医学研究院 | 抗CD2v-N的特异性抗体及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
ZA988461B (en) * | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
DE60100814T2 (de) | 2000-06-08 | 2004-07-01 | Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh | Immunstimulierende oligodeoxynukleotide |
AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
AU2001289813B2 (en) | 2000-08-17 | 2005-07-28 | Intercell Ag | A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
DE60221004T2 (de) | 2001-05-21 | 2008-03-13 | Intercell Ag | Immunostimulierende oligodeoxyribonuklein moleküle |
US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
KR20090003308A (ko) * | 2006-03-02 | 2009-01-09 | 온코세라피 사이언스 가부시키가이샤 | Reg4 단백질을 이용한 췌장암 진단 방법 |
CN101448857A (zh) * | 2006-03-21 | 2009-06-03 | 惠氏公司 | 预防和治疗淀粉样蛋白生成疾病的方法 |
US20070253950A1 (en) * | 2006-03-21 | 2007-11-01 | Wyeth | Methods for Preventing and Treating Amyloidogenic Diseases |
JP2009541275A (ja) * | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
CN100586960C (zh) * | 2006-06-23 | 2010-02-03 | 陈志南 | HAb18GC2单抗和其轻、重链可变区基因及应用 |
WO2008137552A2 (en) * | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
KR101649189B1 (ko) * | 2008-05-09 | 2016-08-18 | 애브비 인코포레이티드 | 최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도 |
-
2010
- 2010-10-08 AU AU2010305374A patent/AU2010305374A1/en not_active Abandoned
- 2010-10-08 KR KR1020127011908A patent/KR20120089863A/ko not_active Application Discontinuation
- 2010-10-08 WO PCT/EP2010/065124 patent/WO2011042548A1/en active Application Filing
- 2010-10-08 CN CN201080045826XA patent/CN102686611A/zh active Pending
- 2010-10-08 EP EP10771381A patent/EP2486058A1/en not_active Withdrawn
- 2010-10-08 BR BR112012007821A patent/BR112012007821A2/pt not_active IP Right Cessation
- 2010-10-08 PE PE2012000444A patent/PE20121689A1/es not_active Application Discontinuation
- 2010-10-08 US US13/500,400 patent/US20120282637A1/en not_active Abandoned
- 2010-10-08 MX MX2012004090A patent/MX2012004090A/es not_active Application Discontinuation
- 2010-10-08 CA CA2777237A patent/CA2777237A1/en not_active Abandoned
- 2010-10-08 JP JP2012532622A patent/JP2013507115A/ja active Pending
- 2010-10-08 RU RU2012118598/10A patent/RU2558301C2/ru not_active IP Right Cessation
-
2012
- 2012-03-22 CR CR20120139A patent/CR20120139A/es unknown
- 2012-03-22 ZA ZA2012/02099A patent/ZA201202099B/en unknown
- 2012-03-27 TN TNP2012000138A patent/TN2012000138A1/en unknown
- 2012-04-01 IL IL218968A patent/IL218968A0/en unknown
- 2012-04-04 MA MA34756A patent/MA33661B1/fr unknown
- 2012-04-05 EC ECSP12011787 patent/ECSP12011787A/es unknown
- 2012-04-05 CL CL2012000886A patent/CL2012000886A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112012007821A2 (pt) | 2017-05-30 |
JP2013507115A (ja) | 2013-03-04 |
IL218968A0 (en) | 2012-07-31 |
KR20120089863A (ko) | 2012-08-14 |
ECSP12011787A (es) | 2012-10-30 |
CA2777237A1 (en) | 2011-04-14 |
RU2012118598A (ru) | 2013-11-20 |
TN2012000138A1 (en) | 2013-09-19 |
MX2012004090A (es) | 2012-04-20 |
RU2558301C2 (ru) | 2015-07-27 |
ZA201202099B (en) | 2012-11-28 |
CN102686611A (zh) | 2012-09-19 |
WO2011042548A1 (en) | 2011-04-14 |
AU2010305374A1 (en) | 2012-05-03 |
CR20120139A (es) | 2012-07-13 |
CL2012000886A1 (es) | 2012-12-14 |
EP2486058A1 (en) | 2012-08-15 |
US20120282637A1 (en) | 2012-11-08 |
MA33661B1 (fr) | 2012-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20121689A1 (es) | Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos | |
PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
PE20121397A1 (es) | Anticuerpos especificos para cadherina-17 | |
PE20060287A1 (es) | INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM | |
PE20140633A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
PE20140247A1 (es) | Anticuerpos anti-cd38 | |
PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
PE20091342A1 (es) | Inmunoglobulinas | |
PE20110771A1 (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
TW200745164A (en) | Gene recombination antibodies composition | |
AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
PE20130159A1 (es) | Anticuerpos anti-cd40 | |
PE20141045A1 (es) | Proteinas de union a bcma (cd269/tnfrsf17) | |
NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
PE20141017A1 (es) | Anticuerpos del cea | |
PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
RS51468B (en) | COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137) | |
PE20081399A1 (es) | Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |